Immunocore Holdings plc (IMCR) Financial Statements
Immunocore Holdings plc (IMCR) reported trailing twelve-month revenue of $430.8M (up 21.0% year on year) and net income of -$18.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$41.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IMCRImmunocore Holdings plcFollow IMCR — free
—
Price chart with a free account
- Market cap
- 1.6B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 0.25 | 0.31 | 0.40 | 0.43 | |
| Gross profit | 0.25 | 0.31 | 0.39 | — | |
| Research & development | 0.16 | 0.22 | 0.27 | 0.28 | |
| Operating income | -0.06 | -0.07 | -0.05 | -0.02 | |
| Pre-tax income | -0.06 | -0.05 | -0.02 | -0.00 | |
| Income tax | -0.01 | -0.00 | 0.02 | 0.02 | |
| Net income | -0.06 | -0.05 | -0.04 | -0.02 | |
| Diluted EPS ($) | -1.13 | -1.02 | -0.71 | -0.37 | |
| Diluted shares (bn) | 0.049 | 0.050 | 0.050 | — |
USD billions · SEC XBRL
Immunocore Holdings plc — questions
- What is Immunocore Holdings plc's revenue?
- $430.8M over the twelve months to 2026-06-30, up 21.0% year on year, from its 10-Q and 10-K filings.
- What is Immunocore Holdings plc's net income?
- -$18.1M over the twelve months to 2026-06-30.
- What is Immunocore Holdings plc's free cash flow?
- -$41.2M over the twelve months to 2026-06-30.
- What are Immunocore Holdings plc's diluted earnings per share?
- $-0.37 over the twelve months to 2026-06-30.
Every figure on this page comes from Immunocore Holdings plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.